On August 27, 2019 Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, reported its participation in the following upcoming investor conferences (Press release, Myovant Sciences, AUG 27, 2019, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-participate-upcoming-september-investor [SID1234539021]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 14th Annual Biotech Conference in Boston, MA. Myovant will host meetings with investors at the conference on Wednesday, September 4, 2019.

Baird 2019 Global Healthcare Conference in New York, NY. Lynn Seely, MD, Myovant’s President and Chief Executive Officer, will participate in a fireside chat on Thursday, September 5, 2019, in a session scheduled to begin at 2:35 p.m. ET.

BioCentury’s 26th Annual Newsmakers in the Biotech Industry Conference in New York, NY. Lynn Seely, MD, will present on Saturday, September 7, 2019, in a session scheduled to begin at 9:00 a.m. ET.
A live webcast of the Baird 2019 Global Healthcare Conference will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay of the webcast will be available at the same location for 30 days following the conference.